Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Adult
Aged
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ antagonists & inhibitors
Cisplatin
/ administration & dosage
Combined Modality Therapy
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Humans
Middle Aged
Neoplasm Metastasis
/ genetics
Nivolumab
/ administration & dosage
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Radiotherapy, Adjuvant
T-Lymphocytes, Cytotoxic
/ drug effects
Triple Negative Breast Neoplasms
/ genetics
Tumor Microenvironment
/ drug effects
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
11
2018
accepted:
19
03
2019
pubmed:
16
5
2019
medline:
16
7
2019
entrez:
16
5
2019
Statut:
ppublish
Résumé
The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer (TNBC) is low
Identifiants
pubmed: 31086347
doi: 10.1038/s41591-019-0432-4
pii: 10.1038/s41591-019-0432-4
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Cisplatin
Q20Q21Q62J
Types de publication
Adaptive Clinical Trial
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
920-928Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Références
Adams, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase 2 KEYNOTE-086 study. Ann. Oncol. https://doi.org/10.1093/annonc/mdy517 (2018).
Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460–2467 (2016).
doi: 10.1200/JCO.2015.64.8931
Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5, 74–82 (2018).
doi: 10.1001/jamaoncol.2018.4224
Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res. Treat. 167, 671–686 (2018).
doi: 10.1007/s10549-017-4537-5
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 380, 987–988 (2018).
Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862–870 (2004).
doi: 10.1016/j.ijrobp.2003.09.012
Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
doi: 10.1038/ncomms15618
Scurr, M. et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin. Cancer Res. 23, 6771–6780 (2017).
doi: 10.1158/1078-0432.CCR-17-0895
de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384–5391 (2014).
doi: 10.1158/1078-0432.CCR-14-1298
Wan, S. et al. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-β signaling in breast cancer cells. PLoS ONE 7, e32542 (2012).
doi: 10.1371/journal.pone.0032542
Alizadeh, D. et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 74, 104–118 (2014).
doi: 10.1158/0008-5472.CAN-13-1545
Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301–1309 (2014).
doi: 10.1038/nm.3708
Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701 (2005).
doi: 10.1084/jem.20050915
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
doi: 10.1016/S1470-2045(17)30074-8
O’Brien, K. M. et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin. Cancer Res. 16, 6100–6110 (2010).
doi: 10.1158/1078-0432.CCR-10-1533
den Brok, W. D. et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res. Treat. 161, 549–556 (2017).
doi: 10.1007/s10549-016-4080-9
Kassam, F. et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer 9, 29–33 (2009).
doi: 10.3816/CBC.2009.n.005
Adams, S. et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase 2 KEYNOTE-086 study. Ann. Oncol. https://doi.org/10.1093/annonc/mdy518 (2018).
Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1–10 (1989).
doi: 10.1016/0197-2456(89)90015-9
Kok, M. et al. Profound immunotherapy response in mismatch repair-deficient breast cancer. JCO Precis. Oncol. 1, 1–3 (2017).
Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
doi: 10.1073/pnas.191367098
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
doi: 10.1172/JCI91190
Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).
doi: 10.1186/s40425-017-0215-8
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
doi: 10.1016/j.cels.2015.12.004
Bezzi, M. et al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat. Med. 24, 165–175 (2018).
doi: 10.1038/nm.4463
Danaher, P., Warren, S. & Cesano, A. Development of gene expression signatures characterizing the tumor–immune interaction. J. Clin. Oncol. 36, 205 (2018).
doi: 10.1200/JCO.2018.36.5_suppl.205
Gu-Trantien, C. et al. CD4
doi: 10.1172/JCI67428
Adams, S. et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 5, 334–342 (2019).
doi: 10.1001/jamaoncol.2018.5152
Loibl, S. et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J. Clin. Oncol. 36, 104 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.104
Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018).
doi: 10.1038/s41591-018-0198-0
Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976–1986 (2018).
doi: 10.1056/NEJMoa1716078
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
doi: 10.1126/science.aaa1348
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
doi: 10.1126/science.aad0095
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
doi: 10.1038/s41588-018-0312-8
Molinero, L. et al. Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo). Cancer Res. 78, abstr. P2-09-13 (2018).
Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).
doi: 10.1126/science.aaf8399
Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl Med. 9, eaah3560 (2017).
doi: 10.1126/scitranslmed.aah3560
Rimm, D. L. et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 3, 1051–1058 (2017).
doi: 10.1001/jamaoncol.2017.0013
Zavalishina, L. et al. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch. 473, 719–724 (2018).
doi: 10.1007/s00428-018-2453-7
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
Baselga, J. et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 31, 2586–2592 (2013).
doi: 10.1200/JCO.2012.46.2408
Singh, J. et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 16, R32 (2014).
doi: 10.1186/bcr3724
O’Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205–214 (2011).
doi: 10.1056/NEJMoa1011418
Carey, L. A. et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30, 2615–2623 (2012).
doi: 10.1200/JCO.2010.34.5579
R Core Team R: a language and environment for statistical computing v3.3.2 (2018).
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 3833702
pmcid: 3833702
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64–70 (2015).
doi: 10.1093/annonc/mdu479
Love, M. I., Hogenesch, J. B. & Irizarry, R. A. Modeling of RNA-seq fragment sequence bias reduces systematic errors in transcript abundance estimation. Nat. Biotechnol. 34, 1287–1291 (2016).
doi: 10.1038/nbt.3682
Nielsen, M., Lundegaard, C., Lund, O. & Kesmir, C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57, 33–41 (2005).
doi: 10.1007/s00251-005-0781-7
Kesmir, C., Nussbaum, A. K., Schild, H., Detours, V. & Brunak, S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng. 15, 287–296 (2002).
doi: 10.1093/protein/15.4.287
Jurtz, V. et al. NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360–3368 (2017).
doi: 10.4049/jimmunol.1700893
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
doi: 10.1093/bioinformatics/btp616
McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012).
doi: 10.1093/nar/gks042
Efron, B. & Thisted, R. Estimating the number of unseen species: how many words did Shakespeare know? Biometrika 63, 435–447 (1976).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Gendoo, D. M. et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics 32, 1097–1099 (2016).
doi: 10.1093/bioinformatics/btv693
Carpenter, B. et al. Stan: a probabilistic programming language. J. Stat. Softw. 76, 1–32 (2017).
doi: 10.18637/jss.v076.i01
Joosse, S. A. et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res. Treat. 116, 479–489 (2009).
doi: 10.1007/s10549-008-0117-z
Schouten, P. C. et al. Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Mol. Oncol. 9, 1274–1286 (2015).
doi: 10.1016/j.molonc.2015.03.002
Vollebergh, M. A. et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 22, 1561–1570 (2011).
doi: 10.1093/annonc/mdq624